Devyser Diagnostics AB Market Cap ($117.78 Million)
Market Cap & Net Worth: Devyser Diagnostics AB (DVYSR)
Devyser Diagnostics AB market cap. Devyser Diagnostics AB (ST:DVYSR) has a market capitalization of $117.78 Million (Skr1.09 Billion) as of November 4, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #18365 globally and #316 in its home market, demonstrating a 28.57% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Devyser Diagnostics AB's stock price Skr64.80 by its total outstanding shares 16889806 (16.89 Million). Also see Devyser Diagnostics AB (DVYSR) cash conversion ratio for how efficiently the company converts equity into cash flow.
Devyser Diagnostics AB Market Cap History (2021–2026)
Devyser Diagnostics AB market cap history from 2021 to 2026. Data shows change from $161.04 Million to $117.78 Million (-6.27% CAGR). Check DVYSR live share price for real-time trading data and today's change.
Index Memberships
Devyser Diagnostics AB is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$15.29 Billion | 0.77% | #29 of 281 |
Weight: Devyser Diagnostics AB's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Devyser Diagnostics AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Devyser Diagnostics AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is Devyser Diagnostics AB growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.83x
Devyser Diagnostics AB's market cap is 0.83 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $161.04 Million | $93.48 Million | -$20.73 Million | 1.72x | N/A |
| 2022 | $130.87 Million | $126.61 Million | -$45.95 Million | 1.03x | N/A |
| 2023 | $142.86 Million | $169.30 Million | -$53.60 Million | 0.84x | N/A |
| 2024 | $215.39 Million | $216.90 Million | -$61.50 Million | 0.99x | N/A |
| 2025 | $207.57 Million | $250.50 Million | -$8.40 Million | 0.83x | N/A |
Competitor Companies of DVYSR by Market Capitalization
Companies near Devyser Diagnostics AB in the global market cap rankings as of November 4, 2026. Also see Devyser Diagnostics AB assets under control for a full breakdown of the balance sheet.
Key companies related to Devyser Diagnostics AB by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #110 globally with a market cap of $190.23 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #204 globally with a market cap of $119.12 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #226 globally with a market cap of $109.30 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #239 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #110 | Abbott Laboratories | NYSE:ABT | $190.23 Billion | $109.40 |
| #204 | Stryker Corporation | NYSE:SYK | $119.12 Billion | $310.55 |
| #226 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $98.88 |
| #239 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Market Capitalization of Devyser Diagnostics AB (2021–2026)
Market capitalization of Devyser Diagnostics AB from 2021 to today. Between 2021 and today, Devyser Diagnostics AB's market cap moved from $161.04 Million to $ 117.78 Million, with a yearly change of -6.27%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr117.78 Million | -43.26% |
| 2025 | Skr207.57 Million | -3.63% |
| 2024 | Skr215.39 Million | +50.76% |
| 2023 | Skr142.86 Million | +9.17% |
| 2022 | Skr130.87 Million | -18.74% |
| 2021 | Skr161.04 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Devyser Diagnostics AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $117.78 Million USD |
| MoneyControl | $117.78 Million USD |
| MarketWatch | $117.78 Million USD |
| marketcap.company | $117.78 Million USD |
| Reuters | $117.78 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Devyser Diagnostics AB
Devyser Diagnostics AB (publ) provides diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories in Sweden, rest of Europe, the Middle East, and Africa. It offers kits and reagents, such as post-transplantation, thalassemia, fetal RHD screening NIPT, Cystic fibrosis cardiovascular diseases, male infertility, rapid aneuploidy analysis, accessories, … Read more